Niraparib (Zejula)
Other Medications · Approved since 2017
Description
Niraparib is an oral PARP (poly ADP-ribose polymerase) inhibitor that has shown activity in colorectal cancer, particularly in patients with homologous recombination deficiency. In CRC treatment, niraparib is being explored as maintenance therapy following oxaliplatin-based chemotherapy and in combination with EGFR inhibitors like panitumumab for advanced or metastatic disease. The drug shows particular promise in colorectal cancers with PALB2 mutations and other DNA repair defects.
Mechanism of Action
Niraparib selectively inhibits PARP-1 and PARP-2 enzymes, which are essential for single-strand DNA break repair through the base excision repair pathway. By blocking PARP function, the drug causes accumulation of DNA damage that leads to synthetic lethality in cancer cells with defective homologous recombination repair, such as those with BRCA1/2, PALB2, or other DNA repair gene mutations.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Zejula |
| Category | Other Medications |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | Oral |
| Year Approved | 2017 |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.